STIM Archives - BioTuesdays

Developments

FDA clears Neuronetics TMS therapy for Anxious Depression

The FDA cleared a new indication for Neuronetics’ (NASDAQ:STIM) transcranial magnetic stimulation (TMS) system – NeuroStar Advanced Therapy for Mental Health – to treat anxiety symptoms for adult patients who suffer...

July 19, 2022

Markets

BTIG cuts Neuronetics to neutral

BTIG downgraded Neuronetics (NASDAQ:STIM) to “neutral” and removed its price target, citing disappointing third quarter preliminary revenue and “perplexing fourth quarter guidance.” The stock closed at $6.40 on Oct. 12...

October 13, 2021

Feature

Keith Sullivan discusses turnaround plan for Neuronetics

As the recently installed president and CEO of Neuronetics (NASDAQ:STIM), a commercial-stage medical device company focused on designing, developing and marketing products that improve the quality of life for patients...

February 23, 2021

Markets

Canaccord ups Neuronetics PT to $20 from $8

Canaccord Genuity raised its price target for Neuronetics (NASDAQ:STIM) to $20 from $8, reflecting the company’s strong fourth quarter preliminary financial results and a new focus on high-margin utilization, compared...

January 19, 2021

Developments

Neuronetics Q4 preliminary revenue tops guidance

Neuronetics (NASDAQ:STIM) reported preliminary unaudited revenue for the fourth quarter of 2020 between $15-million and $15.5-million, compared with previous guidance of $13-million and $13.5-million. “During the...

January 13, 2021

Developments

FDA clears Neuronetics TouchStar protocol for major depressive disorder

The FDA cleared Neuronetics’ (NASDQ:STIM) TouchStar protocol for the treatment of major depressive disorder. TouchStar is a three-minute intermittent theta burst protocol administered using the company’s NeuroStar...

November 24, 2020

Markets

BTIG ups Neuronetics PT to $10 from $6

BTIG raised its price target for Neuronetics (NASDAQ:STIM) to $10 from $6, citing takeaways from recent virtual investor meetings, which focused on how the company’s new CEO, Keith Sullivan, will be reshaping the...

October 6, 2020

Executive Moves

Neuronetics names Keith Sullivan as president and CEO

Keith Sullivan Neuronetics (NASDQ:STIM) appointed Keith Sullivan as president and CEO, effective immediately. Christopher Thatcher, the company’s previous president and CEO, resigned in March 2020. Mr. Sullivan has more...

July 14, 2020

Markets

WB cuts Neuronetics to market perform

William Blair downgraded Neuronetics (NASDAQ:STIM) to “market perform,” citing added uncertainty from COVID-19 headwinds and a commercial restructuring. The stock was quoted at $2.20, down 16 cents, in afternoon trading...

May 5, 2020

Markets

Analysts cuts Neuronetics PTs citing COVID-19 impact

Analysts for BTIG and Canaccord Genuity slashed their price target for Neuronetics (NASDAQ:STIM) but maintained their “buy” ratings, citing a potential leaner post-pandemic business model. Neuronetics markets the...

April 9, 2020

Tag - STIM

FDA clears Neuronetics TMS therapy for Anxious Depression

BTIG cuts Neuronetics to neutral

Keith Sullivan discusses turnaround plan for Neuronetics

Canaccord ups Neuronetics PT to $20 from $8

Neuronetics Q4 preliminary revenue tops guidance

FDA clears Neuronetics TouchStar protocol for major depressive disorder

BTIG ups Neuronetics PT to $10 from $6

Neuronetics names Keith Sullivan as president and CEO

WB cuts Neuronetics to market perform

Analysts cuts Neuronetics PTs citing COVID-19 impact

General

More